Comparative Bioavailability Study of Carbidopa/LevodopaExtended-ReleaseTablets Under Fasting and Fed Conditions Comparative Bioavailability Study of Carbidopa/LevodopaExtended-ReleaseTabletsUnder Fasting and Fe ...
An Open-label, Balanced, Randomized, Five-treatment, Five-period, Five-sequence, Multiple Oral Dose, Crossover Comparative Bioavailability Study of Different Strengths of Carbidopa/LevodopaExtended-releaseTablets With Carbidopa and Levodopa Tablets in Normal, Healthy Adult Human Subjects Under Fasting and Fed Conditions An Open-label, Balanced, Randomized, Five-treatment, Five-period, Five-sequence, Multiple Oral Dose, ...
An Open Label, Balanced, Randomised, Four-treatment, Four-period, Four-sequence, Single Oral Dose, Crossover PK Study of WD-1603 in Normal, Healthy, Adult Human Subjects Under Fed Conditions An Open Label, Balanced, Randomised, Four-treatment, Four-period, Four-sequence, Single Oral Dose, C ...
WD-1603 PK Study Under Fasting and Fed Conditions in Healthy Subjects
AN OPEN LABEL, BALANCED, RANDOMISED, FOUR-TREATMENT, FOUR-PERIOD, FOUR-SEQUENCE, SINGLE INTRA-ORAL AND ORAL DOSE, CROSSOVER PHARMACOKINETICS STUDY OF WD-1603EXTENDED-RELEASECARBIDOPA/LEVODOPATABLETS 25/100MG IN NORMAL, HEALTHY, ADULT HUMAN SUBJECTS UNDER FASTING AND FED CONDITIONS AN OPEN LABEL, BALANCED, RANDOMISED, FOUR-TREATMENT, FOUR-PERIOD, FOUR-SEQUENCE, SINGLE INTRA-ORAL A ...
Parkinson Disease
Drug: WD-1603 CARBIDOPA and LEVODOPA EXTENDED-RELEASETABLETS